Loading...
Market
Will clinical trials for vortioxetine as a glioblastoma treatment begin by December 31, 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Clinical trial registries, ETH Zurich announcements, or reputable medical news sources
Story
£40 Antidepressant Vortioxetine Found Effective Against Glioblastomas in ETH Zurich Study
Sep 20, 2024, 10:29 AM
Researchers have discovered that vortioxetine, a widely available antidepressant costing £40, shows unexpected effectiveness in treating glioblastomas, the most common and aggressive type of brain tumour. Studies conducted in cell cultures and mice by ETH Zurich and other research teams demonstrated that the drug can shrink tumours and kill tumour cells. This breakthrough suggests that vortioxetine could be repurposed to combat glioblastomas, offering a potentially new treatment avenue for this deadly brain cancer.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%